Search
ESPIRIT study
Study characteristics
1) 2739 patients with transient ichemic attack or minor ischemic stroke
2) randomized controlled trial
3) mean follow-up 3.5 years
Treatment groups:
1) aspirin 30-325 mg QD
2) aspirin 30-325 mg QD plus pyridamole 200 mg BID
Combined endpoint:
- vascular death, non-fatal stroke, non-fatal MI, major bleeding
Results:
1) significantly fewer patients in combined aspirin plus dipyridamole group reached combined endpoint (13% vs 16%)
2) significantly more patients in combined aspirin plus dipyridamole group discontinued therapy (34% vs 13%), largely due to headache
General
ischemic stroke prevention trial
References
- The ESPIRIT Study Group.
Aspirin plus dipyridamole versus aspirin alone after cerebral
ischemia of arterial origion (ESPIRIT): Randomized controlled
clinical trial.
Lancet 2006; 367:1665
PMID: 16714187
- Norrving B
Dipyridamole with aspirin for secondary stroke prevention.
Lancet 2006; 367:1638
PMID: 16714170